Related Experiment Video
Updated: Jan 14, 2026

Discovery of Metastatic Regulators using a Rapid and Quantitative Intravital Chick Chorioallantoic Membrane Model
Published on: February 3, 2021
A Novel Multi-Tiered Hybrid Virtual Screening Pipeline for the Discovery of WDR5-MLL1 Interaction Disruptors in
Anwar Abuelrub1,2,3, Ismail Erol1,4, Serdar Durdağı1,2,5
1Laboratory for Innovative Drugs (Lab4IND), Computational Drug Design Center (HİTMER), Bahçeşehir University, İstanbul 34734, Türkiye.
Abstract:
WD Repeat-containing protein 5 (WDR5) is a critical companion for the mixed lineage leukemia (MLL) complex, essential for epigenetic regulation and implicated in various cancers, particularly leukemia. Overexpression of WDR5 in malignant tissues is linked to poor clinical outcomes and enhanced cancer cell proliferation. Its interaction with the MLL1 protein occurs via the WDR5 protein, which is vital for the MLL complex's methyltransferase activity. Recent studies highlight the WIN site as a promising therapeutic target, especially for MLL-rearranged leukemia. In this study, we investigated the structural dynamics of the WDR5-MLL1 complex and aimed to identify potential small-molecule inhibitors targeting the WIN site, to develop novel therapeutic strategies for leukemia and other WDR5 protein-dysregulated cancers. Utilizing the crystal structures of the WDR5 and MLL1, we screened around one million synthetically available compounds from ChemDiv, Enamine, and Specs small molecule libraries. The computational analysis was conducted through comprehensive all-atom molecular dynamics (MD) simulations to evaluate ligand-receptor interaction affinities and involved binding residues. The simulations revealed key participating amino acid residues while quantifying binding affinities using the Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) approach. Steered molecular dynamics (sMD) simulations were further conducted to assess the stability of ligand-receptor interactions of the selected top-compounds. Additionally, novel potential compounds were generated using BRICS fragmentation and Monte Carlo tree search algorithms. Our analysis revealed diverse interaction patterns and potential inhibitory mechanism among the screened compounds. Several compounds, such as Z88418521 and Z116334910, displayed stronger predicted binding affinities than the reference molecule IA9, exhibiting competitive and allosteric modulation of the WDR5-MLL1 complex interaction. A thorough analysis of WDR5 protein and WDR5-MLL1 interactions and their conformational changes offered valuable perspectives on targeting the WDR5-MLL1 complex interaction. Thus, this study profiles the molecular alterations that occur during WDR5-MLL1 complex inhibition, offering crucial mechanistic insights that establish a solid framework for developing targeted treatments for MLL-rearranged leukemia. The distinctive binding characteristics and conformational dynamics exhibited by the identified compounds provide a compelling foundation for future experimental approaches to leukemia intervention.
Insights
Researchers identified novel small-molecule inhibitors targeting the WDR5-MLL1 complex, crucial for epigenetic regulation and implicated in leukemia. These compounds show promise for developing new targeted therapies for MLL-rearranged leukemia and other cancers.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Pharmacology
Background:
- WD Repeat-containing protein 5 (WDR5) is a key component of the mixed lineage leukemia (MLL) complex, vital for epigenetic regulation and linked to various cancers, especially leukemia.
- Overexpression of WDR5 correlates with poor prognosis and increased proliferation in malignant tissues.
- The WDR5-MLL1 interaction is essential for the MLL complex's methyltransferase activity, making the WIN site a promising therapeutic target for MLL-rearranged leukemia.
Purpose of the Study:
- To investigate the structural dynamics of the WDR5-MLL1 complex.
- To identify potential small-molecule inhibitors targeting the WIN site of the WDR5-MLL1 complex.
- To develop novel therapeutic strategies for leukemia and other cancers involving WDR5 dysregulation.
Main Methods:
- Screening of approximately one million compounds from diverse chemical libraries (ChemDiv, Enamine, Specs).
- All-atom molecular dynamics (MD) simulations to assess ligand-receptor interactions and binding affinities (MM-GBSA).
- Steered molecular dynamics (sMD) simulations to evaluate the stability of top-compound-receptor interactions; novel compound generation using BRICS fragmentation and Monte Carlo tree search.
Main Results:
- Identification of several compounds, including Z88418521 and Z116334910, with superior predicted binding affinities compared to the reference molecule IA9.
- Demonstration of competitive and allosteric modulation of the WDR5-MLL1 complex by the identified compounds.
- Detailed analysis of WDR5-MLL1 interactions, conformational changes, and binding mechanisms, providing insights into inhibitory strategies.
Conclusions:
- The study provides crucial mechanistic insights into the inhibition of the WDR5-MLL1 complex.
- Identified compounds offer a strong foundation for developing targeted therapies for MLL-rearranged leukemia.
- The distinct binding characteristics and conformational dynamics of these compounds pave the way for future experimental leukemia interventions.
More Related Videos
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023